[{"address1": "1800 Owens Street", "address2": "Suite 900", "city": "San Francisco", "state": "CA", "zip": "94158", "country": "United States", "phone": "415 906 4324", "website": "https://www.vir.bio", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.", "fullTimeEmployees": 587, "companyOfficers": [{"maxAge": 1, "name": "Dr. Marianne  De Backer M.B.A., M.Sc., Ph.D.", "age": 54, "title": "CEO & Director", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 4467539, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ann M. Hanly Ph.D.", "age": 53, "title": "Executive VP & Chief Technology Officer", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 896072, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jeff  Calcagno M.D.", "age": 62, "title": "Executive VP & Chief Business Officer", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 860494, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Klaus  Frueh Ph.D.", "age": 63, "title": "Co-Founder & Scientific Advisor", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 177661, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Lawrence  Corey M.D.", "age": 76, "title": "Co-Founder & Scientific Advisor", "yearBorn": 1947, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Louis J. Picker M.D.", "title": "Co-Founder & Scientific Advisor", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jennifer Eileen Towne Ph.D.", "title": "Executive VP & Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Heather Rowe Armstrong", "title": "Vice President of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Vanina De Verneuil J.D.", "title": "Executive VP, General Counsel & Corporate Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jenny  Gumm Ed.D., M.B.A.", "title": "Executive VP & Chief Human Resources Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 4, "boardRisk": 6, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 10, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 7.6, "open": 7.65, "dayLow": 7.52, "dayHigh": 7.76, "regularMarketPreviousClose": 7.6, "regularMarketOpen": 7.65, "regularMarketDayLow": 7.52, "regularMarketDayHigh": 7.76, "beta": 0.461, "forwardPE": -2.0291777, "volume": 591915, "regularMarketVolume": 591915, "averageVolume": 1035538, "averageVolume10days": 566340, "averageDailyVolume10Day": 566340, "bid": 7.61, "ask": 7.7, "bidSize": 100, "askSize": 100, "marketCap": 1071428416, "fiftyTwoWeekLow": 7.52, "fiftyTwoWeekHigh": 13.09, "priceToSalesTrailing12Months": 13.583534, "fiftyDayAverage": 9.0592, "twoHundredDayAverage": 9.674675, "currency": "USD", "enterpriseValue": 1908739, "floatShares": 91515719, "sharesOutstanding": 136640000, "sharesShort": 5630762, "sharesShortPriorMonth": 4745637, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.041199997, "heldPercentInsiders": 0.114420004, "heldPercentInstitutions": 0.75136, "shortRatio": 6.59, "shortPercentOfFloat": 0.0672, "bookValue": 10.496, "priceToBook": 0.72884905, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -483040000, "trailingEps": -3.58, "forwardEps": -3.77, "pegRatio": -0.35, "enterpriseToRevenue": 0.024, "enterpriseToEbitda": -0.004, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "VIR", "underlyingSymbol": "VIR", "shortName": "Vir Biotechnology, Inc.", "longName": "Vir Biotechnology, Inc.", "firstTradeDateEpochUtc": 1570800600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ebff203c-69dd-36be-a47c-35beb1571fec", "gmtOffSetMilliseconds": -14400000, "currentPrice": 7.65, "targetHighPrice": 110.0, "targetLowPrice": 15.0, "targetMeanPrice": 33.86, "targetMedianPrice": 21.0, "recommendationMean": 2.2, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 1151064960, "totalCashPerShare": 8.424, "ebitda": -500212000, "totalDebt": 114513000, "quickRatio": 12.014, "currentRatio": 12.506, "totalRevenue": 78877000, "debtToEquity": 7.987, "revenuePerShare": 0.584, "returnOnAssets": -0.16547, "returnOnEquity": -0.29782, "freeCashflow": -303539744, "operatingCashflow": -450992992, "revenueGrowth": -0.19, "operatingMargins": -43.042282, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]